Trial Profile

A Randomized, Evaluator-Blinded, Phase 2 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid (Zyvox®) in the Treatment of Adults With Complicated Skin and Skin Structure Infection (cSSSI)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid
Indications Skin and soft tissue infections; Staphylococcal infections
Focus Therapeutic Use
Sponsors Paratek Pharmaceuticals

05 Jun 2017 Results of pooled post-hoc analysis presented at the ASM Microbe 2017
12 Apr 2016 Results of a pooled analysis (n=377) from this and other phase III trial (see profile 32711) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
11 Apr 2016 Results of pooled analysis (n=377) from this and other phase III trial (see profile 32711) published in the Paratek Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com